BeiGene Targets $4.9B-$5.3B Revenue for 2025 With Strong BRUKINSA and Pipeline Growth
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday
BEIGENE (688235.SH) had a total operating income of 8.048 billion yuan in the first quarter, representing a year-on-year increase of 50.2%.
BEIGENE (688235.SH) announced its main financial data for the first quarter of 2025. During the reporting period, the company...
BEIGENE (06160) showed strong growth in Q1 2025, achieving quarterly GAAP profitability for the first time.
On May 7, 2025, BEIGENE (06160) released its first quarter earnings report for US stocks and a performance forecast for A-shares.
BeiGene Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results.
BEIGENE (06160.HK) reported an adjusted Net income of 0.136 billion USD in the first quarter, marking its first rise to the top position in the overall share of the BTK inhibitor market.
On May 7, Gelonghui reported that BEIGENE (06160.HK) announced that in the first quarter of 2025, the company's total revenue reached 1.1 billion USD, representing a year-on-year increase of 49%; benefiting from strong market demand, the global sales of BeiYueZe (Zebutinib) reached 0.792 billion USD, up 62% year-on-year. In the first quarter of 2025, the USA continued to be the company's largest market, with product revenue of 0.563 billion USD, compared to 0.351 billion USD in the same period last year. Products licensed from Amgen and the sales of BaiZeAn also contributed to the growth in product revenue. In the first quarter of 2025, gross profit under GAAP accounted for
